# TandemAI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tandemai

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.tandemai.com
- Total disclosed funding: $62M
- Latest round: Series A (Nov 14, 2025)
- Investors on record: 8

## About

Based in Shanghai, China, and established in 2021, TandemAI is an innovative drug discovery that take the technology of artificial intelligence. The company has built its networked platform from the ground up in the US and China to increase the speed of drug discovery and deliver cost effective opportunities to the global scientific community. The company's co-founder is Mr. He who has more than 20 years of experience in senor business leadership roles at companies, including at most recently at HiFiBiO, where he served as co-founder and COO, and Harbour BioMed, where he was a co-founder and CFO. And the company's co-founder is Mr Wei Tang, Ph.D., who served at Merck in several senior research roles, with his latest position as a Distinguished Senior Investigator.

The company provides new drug discovery service. The company developed proprietary AI-driven, high-performance computational platform with wet labs for biophysics, medicinal chemistry, and biology in order to accelerate the design and optimization of drug candidates for partners.

The company plans to advance the company's proprietary and computational platform and support expansion of wet lab capacity.

## Funding rounds

- Series A, Nov 14, 2025, $22M — OrbiMed Advisors, Chengwei Capital, Qiming Venture Partners, V-Capital, HSG, Beijing Xinneng Venture Capital
- Series A, Mar 1, 2023, $35M — OrbiMed Advisors, Qiming Venture Partners, Eight Roads Ventures, F-Prime Capital
- Seed, Dec 14, 2021, $5M — Chengwei Capital

## Investors

- Chengwei Capital (https://capitalatlas.ai/funds/chengwei-capital) — Seed, Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- V-Capital (https://capitalatlas.ai/funds/v-capital) — Series A
- HSG (https://capitalatlas.ai/funds/hsg) — Series A
- Beijing Xinneng Venture Capital (https://capitalatlas.ai/funds/beijing-xinneng-venture-capital) — Series A